Reasons Why mHealth Apps Matters for Pharma

The potential of mHealth solutions has been discussed for many years, but only recently, with the advent of the new smartphone application based mHealth model, have pharmaceutical companies begun to realize how mobile services might be instrumental in the development of exciting innovations in their own businesses.

The pharma market has always been cash-rich, as it needs to be given the investment required to continue the research and development behind the medical advances which have made such a difference to humanity. Nonetheless increasing pressure from regulators, thin pipelines and the patent cliff which has seen the rise of generics is a threat to continued prosperity. Innovative business models will help pharmaceutical manufacturers to remain competitive amidst these challenges.

Pharma companies should understand that mobile applications are an innovation area that matters. research2guidance presents 8 good reasons why smartphone apps matter to pharma:

1. Potential reach: Today the smartphone and mHealth markets are still small, but enormous growth rates will enable pharma companies to reach out to every 5th citizen on earth in 2015.

2. Differentiation: The potential for smartphone apps to support patient adherence and compliance makes them the ideal add-on for pharmaceutical products. Therapy supporting pharma applications for example will not only be providing a service, they will also differentiate their products from those offered by the competition.

3. Facilitate improved outcomes for patients taking the company's drugs: The success of a therapy is dependent upon correct compliance. Mobile applications provide the opportunity for pharmaceutical manufacturers to support patients by supplying applications that assist patients in achieving compliance, thereby improving patient outcomes.

4. Contemporary marketing: Physicians are already using smartphones and tablets to access healthcare related information. For pharmaceutical companies it would make sense to re-allocate marketing budgets spent on printed medical reference and CME programs to applications. They cost a fraction of what printed materials cost, are more innovative, represent a real value of less than $5, and fit into the regulatory framework in even the strictest systems.

5. Learn how patients use their medicine: Mobile applications offer a direct channel of communication between the manufacturer of a pharmaceutical product and the patient. Applications provide direct usage information, which can assist in understanding the usage habits of patients.

6. Saving costs: Smartphone apps have the potential to offer various cost-saving areas for pharmaceutical companies. Examples would be applications that support the exchange of results in medical trials, information on customers that would be useful to review before meeting with them, etc.

7. Improve relations with doctors: Apps are very personal tools, more so than websites of medical books. Visiting doctors is an essential but expensive aspect of pharma marketing, and the opportunity to connect directly with physicians by providing a useful app would be a good way to create new relationships with prescribing healthcare professionals.

8. Increasing revenue: Some mHealth solutions (like "patient monitoring" applications) might become the block-busters of the future, selling millions for a subscription of $10-$20 per month, even with the price for mHealth apps at between $5 and $10.

Please see research2guidance's Mobile Health Market Report 2010-2015 for more details and a detailed discussion on business opportunities for Pharma companies based on the new smartphone based mHealth market model.

About research2guidance
research2guidance is a Berlin-based market research company specialized in the mobile industry. The company's service offerings include comprehensive market studies, as well as bespoke research and consultancy. For more information, visit www.research2guidance.com.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...